Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells
© Zakaria et al.; licensee BioMed Central. 2015
Received: 15 October 2014
Accepted: 12 February 2015
Published: 25 February 2015
Despite significant advances in staging and therapies, lung cancer remains a major cause of cancer-related lethality due to its high incidence and recurrence. Clearly, a novel approach is required to develop new therapies to treat this devastating disease. Recent evidence indicates that tumours contain a small population of cells known as cancer stem cells (CSCs) that are responsible for tumour maintenance, spreading and resistant to chemotherapy. The genetic composition of CSCs so far is not fully understood, but manipulation of the specific genes that maintain their integrity would be beneficial for developing strategies to combat cancer. Therefore, the goal of this study isto identify the transcriptomic composition and biological functions of CSCs from non-small cell lung cancer (NSCLC).
We isolated putative lung CSCs from lung adenocarcinoma cells (A549 and H2170) and normal stem cells from normal bronchial epithelial cells (PHBEC) on the basis of positive expression of stem cell surface markers (CD166, CD44, and EpCAM) using fluorescence-activated cell sorting. The isolated cells were then characterised for their self-renewal characteristics, differentiation capabilities, expression of stem cell transcription factor and in vivo tumouregenicity. The transcriptomic profiles of putative lung CSCs then were obtained using microarray analysis. Significantly regulated genes (p < 0.05, fold change (FC) > 2.0) in putative CSCs were identified and further analysed for their biological functions using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).
The putative lung CSCs phenotypes of CD166+/CD44+ and CD166+/EpCAM+ showed multipotent characteristics of stem cells, including the ability to differentiate into adipogenic and osteogenic cells, self-renewal, and expression of stem cell transcription factors such as Sox2 and Oct3/4. Moreover, the cells also shows the in vivo tumouregenicity characteristic when transplanted into nude mice. Microarray and bioinformatics data analyses revealed that the putative lung CSCs have molecular signatures of both normal and cancer stem cells and that the most prominent biological functions are associated with angiogenesis, migration, pro-apoptosis and anti-apoptosis, osteoblast differentiation, mesenchymal cell differentiation, and mesenchyme development. Additionally, self-renewal pathways such as the Wnt and hedgehog signalling pathways, cancer pathways, and extracellular matrix (ECM)-receptor interaction pathways are significantly associated with the putative lung CSCs.
This study revealed that isolated lung CSCs exhibit the characteristics of multipotent stem cells and that their genetic composition might be valuable for future gene and stem cells therapy for lung cancer.
KeywordsCancer stem cells Non-small cell lung cancer Cell surface marker Transcriptome
Lung cancer is one of the most common malignancies throughout the world. It accounted for about 16.1 million deaths in 2008 and is the leading cause of cancer-related death . Based on pathological features, lung cancer is classified into two major groups; small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). The majority of lung cancer cases are NSCLC (80%). NSCLC is less aggressive than SCLC. NSCLC tends to grow and spread slower than SCLC, which is fast growing and rapidly spreads to the bloodstream and other parts of the body. The three main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma. The prognosis for patients with NSCLC remains very poor, with only 15% survival within 5 years after treatment [2,3]. Moreover, the recurrence rate ranges from 35% to 50% among early stage NSCLC patients: After an apparently successful initial therapy, development of secondary tumours often leads to a lethal relapse.
The biological characteristics associated with the aggressive behaviour of cancer cells is driven by a subpopulation of cells within the tumour called cancer stem cells (CSCs) [4,5]. CSCs were first described in human hematopoietic cancer, and to date they have been identified in solid tumours of breast , pancreas , brain , and colon [9,10] cancers. CSCs can self-renew, initiate tumour development, and differentiate into multiple cell types [4,11-13], and recent evidence suggests that these cells play a central role in the progression of malignant tumours. The CSCs model describes the existence of a small subpopulation of plastic cells with transdifferentiation potential in tumours. However, recent studies suggest that a major proportion of cells within tumours maintain stem cell properties and even more differentiated cells can be transformed into stem-like cells [13,14]. If this is the case, eradication of CSCs might not be a useful strategy for the reduction of tumour growth. Therefore, it is important to understand CSCs biology and identify new strategies to prevent malignant tumour progression. The mechanisms that regulate self-renewal of both CSCs and normal stem cells are thought to be similar .
Currently, identification and isolation of CSCs is largely dependent on the presence of specific cell surface markers [10,15], although the expression of such markers depends on various factors (e.g., the differentiation state of the cells and niche factors). Many of the markers used to identify CSCs are derived from the surface markers known to be present on normal hematopoietic or embryonic stem cells. CD133 has been used as a putative stem cell marker in glioblastoma  and colon cancer ; CD34 expressing tumour epithelial cells have been used as a marker in cutaneous cancer ; and CD44 expressing cells have been used as a marker in breast cancer . Moreover, CD26 positive cells are indicative of metastases, invasiveness, and chemoresistance in colon cancer, and CD271 positive cells initiate melanoma progression and metastasis . For lung CSCs, CD133 , CD166 , EpCAM, CD90, and CD44 [15,22] have been used as markers. CD133 is a well-described CSCs marker in various types of cancers, including hematopoietic , brain , colon , pancreatic , and lung  cancers. In NSCLC and SCLC patient samples, CD133+ cells possess tumourigenic and self-renewal characteristics . However, several studies suggest that the use of CD133 expression to discriminate lung CSCs is overstated. For example, some CD133− lung cancer cells also possess the ability to self-renew and generate the formation of xenograft when transplanted into recipient mice . Unlike in gliomas, where CD133 is a more established cancer stem cell marker, CD133 expression in lung cancer is not associated with patient prognosis [25-27]. Moreover, in many lung cancer samples, CD133 is not detected [26-28]. Recently, few scientists have questioned the use of CD133 as a selective CSCs marker in other solid tumour types, citing cases where CD133ˉ cells also possess the capacity for self-renewal and cancer initiation [29,30]. Based on these data, we exclude CD133 in this study and focus only on CD166, CD44, and EpCAM.
The goal of this study is to identify and characterise the CSCs population in human NSCLC using CD166, CD44, and EpCAM as markers. We also conducted transcriptomic profiling of the isolated CSCs to determine how the transcriptome is involved in the signaling pathways specific to the CSCs of lung cancer.
The human lung cancer cell lines A549 (lung carcinoma) and H2170 (squamous cell carcinoma) and the normal primary human bronchial/tracheal epithelium (PHBEC) cell line were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).
The cancer cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were incubated in a humidified incubator at 37°C and 5% CO2. Cells were maintained in 75 cm2 tissue culture flasks and harvested by 0.25% trypsin-EDTA treatment when they reached 80% confluency. Unless specified, all reagents were obtained from Gibco (Life Technologies, Foster City, CA, USA).
PHBECs were cultured in specific airway epithelial cell medium purchased from ATCC. The medium consists of airway epithelial cell basal medium (PCS-300-030) supplemented with the bronchial/tracheal epithelial growth kit (PCS-300-040), gentamicin-amphoterin B solution (PCS-999-025), penicillin-streptomycin-amphoterin B Solution (PCS-999-002), and phenol red (PCS-999-001). The cells were incubated in a humidified incubator at 37°C and 5% CO2. Cells were maintained in 75 cm2 tissue culture flasks and harvested using 0.05% Trypsin-EDTA when they reached 80% confluence.
Isolation of putative CSCs and normal stem cells
The lung cancer cells and normal cells were detached with trypsin and washed with phosphate buffer solution (PBS) containing 2% FBS (PBS/2% FBS). The cell suspensions were then labelled with antibodies CD44-FITC (Clone: L178; Isotype: Mouse IgG1, κ), CD166-PE (Clone: 3A4; Isotype: Mouse IgG1, κ) (BD Biosciences, San Jose, CA, USA), and EpCAM–FITC (Clone: 158206; Isotype: Mouse IgG2B; Isotype: Mouse IgG1, κ) (R&D System, Minneapolis, MN, USA). Briefly, the cells were resuspended in 90 μL of PBS/2% FBS. Next, 10 μL of each antibody were added to the cell suspensions and incubated for 30 min on ice and in the dark. At the end of the incubation, unbound antibodies were washed away with PBS. Each cells pellet was resuspended in 300–500 μL PBS/2% FBS and filtered through a 40 μm cell strainer to obtain a single cell suspensions before sorting. The expression of cancer stem cell markers (CD166, CD44, and EpCAM) was analysed and populations of cells expressing the markers were sorted using a fluorescence-activated cell sorter (FACSAria III, BD Biosciences). The sorting for each cell population was done in three independent experiments to represent the biological variation.
Adipogenic, chondrogenic, and osteogenic differentiation in vitro
The putative CSCs were induced to differentiate into different lineages using adipogenic, chondrogenic, and osteogenic differentiation media (PromoCell, Heidelberg Germany). Briefly, the putative CSCs were seeded in 24-well tissue culture plates until the cells reached 80–90% confluence (for adipogenic differentiation) or 100% confluence (for chondrogenic and osteogenic differentiation). The initial seeding number was 6 × 104 cells for adipogenic and chondrogenic differentiation and 1 × 105 cells for osteogenic differentiation. Once the cells reached the required confluency, two sets of triplicate wells were induced to differentiate by replacing the culture medium with the specific differentiation medium. The remaining wells containing the normal medium served as the control. The cells were incubated for 14 days (adipogenic differentiation) and 21 days (chondrogenic and osteogenic differentiation), and the medium was changed every 3 days.
Detection of differentiation in vitro
At the end of the incubation period, the cells were washed with PBS, fixed with 10% buffered formalin, and stained with a respective staining solution to detect adipocyte, chondrocyte, or osteocyte formation. Formation of adipocytes was detected by observing intracellular lipid vesicles stained red by 0.3% Oil Red O (Sigma-Aldrich, Munich, Germany). After the cells were fixed, they were incubated with 60% isopropanol at room temperature for 5 min. The isopropanol was carefully aspirated, and Oil Red O staining solution was added to cover the cells. The cells were incubated for 15 min, washed several times with distilled water, and counterstained with a Harris Hematoxylin solution for 1 min. Lastly, the cells were washed with distilled water and observed under the microscope.
Osteocyte formation was detected by staining calcium deposits with 2% Alizarin Red S (Sigma-Aldrich). The fixed cells were incubated with Alizarin Red S staining solution for 45 min at room temperature in the dark. The cells were washed four times with distilled water, and PBS was then added to each well. When observed under the microscope, extracellular calcium deposits were stained bright orange-red. Chondrogenic differentiation was detected by staining with Alcian blue staining solution (Sigma-Aldrich). The fixed cells were incubated with Alcian blue staining solution overnight at room temperature in the dark. The cells were washed four times with distilled water, and PBS then was added to each well. When observed under the microscope, the cartilages were stained an intense dark-blue, whereas other tissue was at most faintly bluish.
Colony forming assay
For the colony forming assay, the cells were trypisinised as described previously. The cells were seeded in 6-well plates at low density (~200 cells per well) and cultured for 7 days. The plates were then washed with PBS and fixed with 10% formalin for 10 min followed by staining with crystal violet for 30 min. The plates were then washed with PBS, and images of each well were captured using an inverted microscope. The experiment was performed in three independent replicates for A549 and H2170 cells.
Sphere forming assay
Isolated putative lung CSCs were cultured in low adherent 35 mm dishes under serum-free conditions and supplemented with 20 ng/ml of epidermal growth factor (EGF) (Life Technologies, Foster City, CA, USA) 10 ng/ml of basic fibroblast growth factor (bFGF) (Life Technologies), and B27 supplement (Life Technologies) for 21 days according to published protocols . The experiment was conducted in three independent replicates for A549 and H2170 cells.
Expression of the stem cell transcription factors
List of primers used in RT-PCR for expression of stem cell transcription factors
In vivo tumourigenicity studies
The ability of the marker-selected cells to initiate in vivo tumour development was investigated by subcutaneous transplantation of cells into nude mice. All experiments were carried out using 4–7 week old female NCR nude mice (INVIVOS, Perahu Rd, Singapore). Mice were maintained in individually ventilated cages (IVC) (Allentown Inc., NJ, United States). The experiments were approved by the Universiti Sains Malaysia Animal Ethics Committee according to the institutional guidelines. For the mouse xenograft, 2 × 104 cells from parental cells, putative CSCs, and putative non-CSCs of both A549 and H2170 cell lines were mixed with matrigel (BD Biosciences) and subcutaneously injected into the right flank of the nude mice (n = 3 for each cell type). Mice were monitored every 2 days between two weeks after inoculation. The mice were sacrifice at day 60 or when the tumour diameter reached at least 1 cm in size. All tumour tissues were collected for morphological and histological analysis.
Total RNA extraction and cDNA synthesis
Total RNA was extracted from up to 1 × 106 CD166+/CD44+ and CD166+/EpCAM+ PHBEC, A549, and H2170 cells using the Qiagen AllPrep DNA/RNA Isolation Kit (Qiagen) according to the manufacturer’s protocol. Briefly, the cells were lysed with lysis buffer and homogenized using the QIAshredder Homogenizer (Qiagen). Ethanol (70%) was then added to the homogenized cell lysates, and the cell lysates were transferred into the RNA spin column. Total RNA that bound to the spin column was eluted from the spin column using RNase free water. The concentration and purity of the extracted RNA were determined using a Nanodrop® ND1000 spectrophotometer, and the RNA integrity number (RIN) was determined using the Bioanalyzer 2100 (Agilent Technologies).
ST-cDNA amplification, purification, fragmentation, and labelling
Total RNA (1.5 μg) was amplified using the Applause™ WT-Amp ST System (Nugen Technologies, Inc., San Carlos, USA) following the manufacturer’s protocol. The seven step amplification process produced ST-cDNA, which was further purified using the MinElute Reaction Cleanup Kit (Qiagen). The yield and purity of the purified ST-cDNA were measured using the Nanodrop® ND1000 spectrophotometer. The A260:A280 ratio must be > 1.8 and the concentration must be in the range of 2 to 2.5 μg for the ST-cDNA to be hybridised to the array. The purified ST-cDNA was then fragmented and labelled with biotin (Nugen Technologies).
Array hybridisation and scanning
Biotin-labelled fragmented ST-cDNA was hybridised to oligonucleotide probes on Affymetrix GeneChip® 1.0 ST arrays and then washed and stained using the GeneChip® Hybridisation Wash and Stain Kit. For each array, 2–2.5 μg of the fragmented biotin-ST-cDNA were hybridised to the arrays for 17 h at 45°C in a rotating hybridisation oven. The array was stained utilizing the FS450_0007 protocol of the Affymetrix Fluidics Station FS450. The arrays were scanned with an Affymetrix Scanner 3000, and data were obtained using the GeneChip® Operating Software. The microarray experiment was performed using three biological replicates for each sample.
Data processing and analysis
Comparison groups in microarray data analysis conducted using gene spring software
A549 CD166+/ CD44+ vs. PHBEC CD166+/CD 44+
A549 CD166+ /EpCAM+ vs. PHBEC CD166+ /EpCAM+
H2170 CD166+ /EpCAM+ vs. PHBEC CD166+ /EpCAM+
List of genes and probe sequences used in the microarray validation assay
Functional enrichment analysis
Functional enrichment analysis was performed using DAVID (http://david.abcc.ncifcrf.gov/) [31,32]. Significantly regulated genes (FC > 2; p < 0.05) from each group were submitted to DAVID. The analysis was started by clicking on “Start Analysis” on the header, and the gene list manager panel that appeared was used to perform the analysis step. First, the list of gene IDs was copied and pasted into box A, an appropriate gene identifier type (gene list or background) for the input gene ID was selected, and the submit button was pressed. If DAVID could not recognize more than 20% of the submitted gene ID, the submission was redirected to the DAVID Gene ID Conversion Tool. Once the list of genes was successfully submitted, the analysis of the list was performed using the available DAVID analysis tools. These tools include functional annotation tools, gene functional classification tools, and the gene name batch viewer.
Expression of cancer stem cell markers in NSCLC cells
Co-expression of CD166 with CD44 and EpCAM to identify the subpopulation of NSCLC cells with stem cell-like properties
Putative lung CSCs exhibit differentiation potential
Self-renewal ability of putative lung CSCs
Putative lung CSCs exhibit stem cell gene expression
In vivo tumourigenicity properties of putative lung CSCs
In vivo tumourigenicity experiment of putative lung CSCs and non-putative CSCs
Cell number injected
Tumour size (average) (cm)
3 / 3
3 / 3
2 / 3
3 / 3
2 / 3
3 / 3
3 / 3
2 / 3
Control (media + matrigel)
0 / 3
Transcriptomic profiling of putative lung CSCs using microarray analysis
Number of significantly regulated genes (p < 0.05, fold change > 2.0) in putative CSCs compared to putative normal stem cells
Number of genes
A549 CD166+/CD44+ vs. PHBEC CD166+/CD44+
A549 CD166+/EpCAM+ vs. PHBEC CD166+/EpCAM+
H2170 CD166+/ EpCAM+ vs. PHBEC CD166+/ EpCAM+
Validation of microarray data by RT-PCR
To verify the expression value of the microarray data, the original amplified RNA samples used for microarray analysis were validated for six genes using RT-PCR. Three of the selected genes were up-regulated and three were down-regulated. The expression values detected by both microarray and RT-PCR techniques were plotted as log2 FC (Figure 7). The Pearson correlation coefficient test showed that the expression values detected by both platforms were in agreement (p < 0.05) (Figure 7).
Functional enrichment analysis of differentially expressed genes in putative CSCs
Common significant pathways associated with up-regulated and down-regulated genes of putative CSCs
MAPK signalling pathway
Wnt signalling pathway
Cell adhesion molecules (CAMs)
Pathways in cancer
Non-small cell lung cancer
p53 signalling pathway
Hedgehog signalling pathway
Pathways in cancer
Small cell lung cancer
Because CSCs likely play an important role in maintaining cancer cell populations, targeting specific components of CSCs regulatory pathways could open up a new strategy for cancer treatment. Identification and isolation of CSCs from NSCLC cells is the initial step in identifying more specific CSCs markers in the NSCLC cell population. We found that CD166 was highly expressed in both normal and lung cancer cells, and we used the combinations of CD166/CD44 and CD166/EpCAM for further analysis.
The flow cytometry analysis revealed that the lung cancer cells consist of a heterogeneous population with different phenotypes (CD166+/CD44+, CD166+/CD44−, CD166−/CD44+, CD166−/CD44−, CD166+/EpCAM+, CD166+/EpCAM−, CD166−/EpCAM+, and CD166−/EpCAM−), which supports the initial hypothesis that the CSCs population is heterogeneous. We hypothesized that the double positive cells (i.e., CD166+/CD44+ and CD166+/EpCAM+) are the putative lung CSCs in A549 and H2170 cells. The putative lung CSCs showed multilineage differentiation and self-renewal capability, which proved that they had the stem cell-like phenotype.
Results of previous studies support the use of CD166, CD44, and EpCAM as CSCs markers. The combination of CD166/CD44 was previously used to identify CSCs from colorectal cancer cell lines; CD166+/CD44+ cells were found to have higher clonogenicity and accelerated tumour development compared to CD166−/CD44− cells, and the observation was cell dependent . To date, there have been no reports of the combination of CD166/CD44 and CD166/EpCAM to identify lung CSCs, but co-expression of other CSCs markers to identify lung CSCs has been reported. For instance, Wang et al. combined CD44 and CD90 to identify lung CSCs . They demonstrated that CD44+/CD90+ cells had therapy resistance and higher colony and spheroid forming potential when compared to CD44+/CD90−, CD44−/CD90+, and CD44−/CD90− cells. Another study combined CD133 with CD44 to identify lung CSCs in A549 cells and found that CD133+/CD44+ cells had significant CSCs properties (i.e., continuous proliferative capacity and differential potential) .
In this study, the expression of surface markers differed between the tested cell lines, even though both are NSCLC cell lines. For example, 61.5% and 0.0% of A549 and H2170 cells, respectively, were CD44+. Other studies using the same A549 cells reported that 84.41%  and 0.0%  of A549 cells expressed CD44. Stuelten et al. also found inconsistent expression of CD44 in nine NSCLC cell lines, including A549 cells . In addition, different expression levels of CD44 have been reported in other types of tumours, including colon, ovarian, and breast cancers . We also found that CD166 and EpCAM expression differed between cell lines. We detected expression of CD166 in 72.9% and 52.56% of A549 and H2170 cells, respectively, whereas the values for EpCAM were 13.8% and 33.8%, respectively. The inconsistent expression profiles of CSCs markers among different studies could be related to individual cancer variations, different potency states, and functional characteristics of the CSCs population. Thus, in the absence of a specific marker, the true percentage of CSCs in a tumour, particularly in long-established cancer cell lines, is controversial . The variation in environmental and selective pressures experienced by cancer cells in vitro and in vivo might trigger or suppress different pathways that regulate CSCs functions, and it is not clear whether the CSCs profiles could vary with circumstances.
The abilities of the CD166+/CD44+ and CD166+/EpCAM+ A549 and H2170 cells to differentiate into adipogenic and osteogenic lineages and to express stem cell transcription factors showed their stem cell characteristics. Moreover, the increased tumorigenic ability of the putative lung CSCs as shown in in vivo study also indicated their cancer stem cells characteristic. Microarray analysis of putative lung CSCs was carried out to better understand the transcriptomic regulation of putative CSCs as compared to normal lung stem cells. Using microarray technology, transcription profiling was performed for putative lung CSCs isolated from the two lung cancer cell lines. The composition of the up-regulated genes and their pathways showed that these genes play an important role in maintaining the stemness of the lung CSCs, whereas the dysregulated genes were involved in cellular repair. The GO term analysis showed consistent results, with the significantly regulated genes of putative CSCs being involved in stem cell related biological and development processes. These findings clearly illustrate that CSCs are present in lung cancer cells and that these isolated putative CSCs possess stem cell characteristics.
The significantly regulated genes identified in our study were involved in the Wnt and hedgehog pathways and were associated with the self-renewal process of normal stem cells . The ability to self-renew is a special characteristic of stem cells, as it allows them to divide and maintain their stemness. Wnt and hedgehog signaling pathways have been reported to play an important role in carcinogenesis as well as in normal stem cell processes [4,38]. In addition, the over-expression of Wnt signaling molecules has been reported to be involved in drug resistance of A549 cells, and up-regulation of this signaling pathway was suggested to be one of the characteristics of CSCs . Our microarray data showed that Wnt signaling was up-regulated only in putative CSCs of A549 cells; it was not detected in H2170 cells. This could explain the higher colony forming ability of A549 cells compared to H2170 cells.
Genes involved in the ECM pathway
Integrin, alpha 2
Integrin, alpha 3
Integrin, alpha 5
Integrin, alpha 6
Integrin, beta 4
Integrin, beta 6
Integrin, beta 8
Laminin, alpha 3
Laminin, beta 3
Laminin, gamma 2
We successfully identified and characterised putative CSCs from NSCLC cells. The CSCs with the CD166+/CD44+ and CD166+/EpCAM+ phenotypes have the ability to differentiate into adipogenic and osteogenic lineages and possess self-renewal ability. The gene expression study revealed that the putative lung CSC transcriptome is significantly associated with stem cells and cancer biological processes, including angiogenesis, migration, pro-apoptosis and anti-apoptosis, osteoblast differentiation, mesenchymal cell differentiation, and mesenchyme development, and is involved in stem cell self-renewal pathways, Wnt and hedgehog signaling, and cancer-associated pathways. This study revealed that isolated putative lung CSCs exhibit the characteristics of multipotent stem cells, and their genetic composition might be valuable for future gene and stem cell therapy for lung cancer.
This study was supported by grants from the Research University Grant scheme (1001/ CIPPT/811204) of Universiti Sains Malaysia.
- Mathers CD, Fat DM, Boerma J. The global burden of disease: 2004 update: World Health Organization; 2008
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.View ArticlePubMedGoogle Scholar
- Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.View ArticlePubMedGoogle Scholar
- Zhou BBS, Zhang HY, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8(10):806–23.View ArticlePubMedGoogle Scholar
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–7.View ArticlePubMedGoogle Scholar
- Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.View ArticlePubMedGoogle Scholar
- O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.View ArticlePubMedGoogle Scholar
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.View ArticlePubMedGoogle Scholar
- Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T, et al. Identification of human brain tumor initiating cells. Nature. 2004;19:396–401.View ArticleGoogle Scholar
- Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140(1):62–73.View ArticlePubMedGoogle Scholar
- Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633–44.View ArticlePubMedGoogle Scholar
- Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci. 2011;108(19):7950–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010;5(11):e14062.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829–33.View ArticlePubMedGoogle Scholar
- Malanchi I. Tumour cells coerce host tissue to cancer spread. BoneKEy Reports 2. 2013; 371.
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504–14.View ArticlePubMedGoogle Scholar
- Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012;148(1–2):259–72.View ArticlePubMedGoogle Scholar
- Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One. 2013;8(3):e57020.View ArticlePubMedPubMed CentralGoogle Scholar
- Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):5002–12.PubMedGoogle Scholar
- Meng X, Li M, Wang X, Wang Y, Ma D. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 2009;100(6):1040–6.View ArticlePubMedGoogle Scholar
- Howard BM, Boockvar JA. Stem cell marker CD133 expression predicts outcome in glioma patients. Neurosurgery. 2008;62(6):N8.View ArticleGoogle Scholar
- Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer J Int du Cancer. 2010;126(4):950–8.Google Scholar
- Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. European J Cardio-Thoracic Surg Off J European Assoc Cardio-Thoracic Surgery. 2009;36(3):446–53.View ArticleGoogle Scholar
- Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009;106(38):16281–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer J Int du Cancer. 2008;122(4):761–8.View ArticleGoogle Scholar
- Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133–metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111.PubMedPubMed CentralGoogle Scholar
- Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):3.View ArticleGoogle Scholar
- da Huang W, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, et al. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8(9):R183.View ArticlePubMedPubMed CentralGoogle Scholar
- Muraro MG, Mele V, Daster S, Han J, Heberer M, Cesare Spagnoli G, et al. CD133+, CD166 + CD44+, and CD24 + CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med. 2012;1(8):592–603.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang H, Lin X, Hua P, Wang M, Ao X, Xiong L, et al. The study of the tumor stem cell properties of CD133+ CD44+ cells in the human lung adenocarcinoma cell line A549. Cell Mol Biol (Noisy-le-Grand, France). 2010;56:OL1350.Google Scholar
- Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, et al. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells. 2010;28(4):649–60.View ArticlePubMedGoogle Scholar
- Alexander CM, Puchalski J, Klos KS, Badders N, Ailles L, Kim CF, et al. Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell. 2009;5(6):579–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–68.View ArticlePubMedGoogle Scholar
- Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843–50.View ArticlePubMedGoogle Scholar
- Teng Y, Wang X, Wang Y, Ma D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun. 2010;392(3):373–9.View ArticlePubMedGoogle Scholar
- Whittaker CA, Bergeron KF, Whittle J, Brandhorst BP, Burke RD, Hynes RO. The echinoderm adhesome. Dev Biol. 2006;300(1):252–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Ozbek S, Balasubramanian PG, Chiquet-Ehrismann R, Tucker RP, Adams JC. The evolution of extracellular matrix. Mol Biol Cell. 2010;21(24):4300–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Raymond K, Deugnier MA, Faraldo MM, Glukhova MA. Adhesion within the stem cell niches. Curr Opin Cell Biol. 2009;21(5):623–9.View ArticlePubMedGoogle Scholar
- Shen Q, Wang Y, Kokovay E, Lin G, Chuang SM, Goderie SK, et al. Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell. 2008;3(3):289–300.View ArticlePubMedPubMed CentralGoogle Scholar
- Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.